Are you Dr. Henderson?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 46 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
707 Hollybrook Dr
Longview, TX 75605Phone+1 903-757-6042Fax+1 903-232-8226
Summary
- Dr. Samuel Henderson, MD is a board certified pathologist in Longview, Texas. He is currently licensed to practice medicine in Texas, Michigan, and Louisiana. He is affiliated with Longview Regional Medical Center.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Dermatopathology, 2013 - 2014- University of Texas M.D. Anderson Cancer CenterSelective Pathology, 2012 - 2013
University of Texas Southwestern Medical CenterResidency, Pathology-Anatomic and Clinical, 2008 - 2012
University of Texas Medical Branch School of MedicineClass of 2008
Certifications & Licensure
TX State Medical License 2012 - 2026
LA State Medical License 2014 - 2025
MI State Medical License 2016 - 2024- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Dermatopathology
Clinical Trials
- Tricaprilin In Age-Associated Memory Impairment Start of enrollment: 2006 Jul 01
- Retrospective Cohort Study Of The Efficacy Of Axona® (Medium Chain Triglycerides) In Patients With Alzheimer's Disease Start of enrollment: 2012 Jan 01
Publications & Presentations
PubMed
- 22 citationsProtein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma.Minerva A. Romero Arenas, Timothy G. Whitsett, Anna Aronova, Samuel A. Henderson, Janine LoBello
Annals of Surgical Oncology. 2018-03-01 - 86 citationsClinical Outcomes of cT1 Micropapillary Bladder CancerDaniel L. Willis, Mario I. Fernández, Rian J. Dickstein, Sahil Parikh, Jay B. Shah
The Journal of Urology. 2015-04-01 - 14 citationsDetection of mitotic figures and G2+ tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinoma.Samuel A. Henderson, Michael T. Tetzlaff, Penvadee Pattanaprichakul, Patricia S. Fox, Carlos A. Torres-Cabala
Journal of Cutaneous Pathology. 2014-11-01
